KR20240036604A - Asgpr 세포 표면 수용체 결합 화합물 및 접합체 - Google Patents

Asgpr 세포 표면 수용체 결합 화합물 및 접합체 Download PDF

Info

Publication number
KR20240036604A
KR20240036604A KR1020247004826A KR20247004826A KR20240036604A KR 20240036604 A KR20240036604 A KR 20240036604A KR 1020247004826 A KR1020247004826 A KR 1020247004826A KR 20247004826 A KR20247004826 A KR 20247004826A KR 20240036604 A KR20240036604 A KR 20240036604A
Authority
KR
South Korea
Prior art keywords
compound
optionally substituted
linker
antibody
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247004826A
Other languages
English (en)
Korean (ko)
Inventor
브렛 브래들리 부슈
저스틴 토머스 언스트
개릭 케이. 패커드
제이슨 쥐. 루이스
에릭 디. 터틀
Original Assignee
리시아 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리시아 테라퓨틱스, 인크. filed Critical 리시아 테라퓨틱스, 인크.
Publication of KR20240036604A publication Critical patent/KR20240036604A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247004826A 2021-07-14 2022-07-14 Asgpr 세포 표면 수용체 결합 화합물 및 접합체 Pending KR20240036604A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221918P 2021-07-14 2021-07-14
US63/221,918 2021-07-14
PCT/US2022/037227 WO2023288033A1 (en) 2021-07-14 2022-07-14 Asgpr cell surface receptor binding compounds and conjugates

Publications (1)

Publication Number Publication Date
KR20240036604A true KR20240036604A (ko) 2024-03-20

Family

ID=82786913

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247004826A Pending KR20240036604A (ko) 2021-07-14 2022-07-14 Asgpr 세포 표면 수용체 결합 화합물 및 접합체

Country Status (8)

Country Link
US (2) US12258332B2 (cg-RX-API-DMAC7.html)
EP (1) EP4370157A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024524614A (cg-RX-API-DMAC7.html)
KR (1) KR20240036604A (cg-RX-API-DMAC7.html)
CN (1) CN117957020A (cg-RX-API-DMAC7.html)
AU (1) AU2022310356A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226269A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023288033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022009419A (es) 2020-01-31 2022-08-25 Avilar Therapeutics Inc Compuestos de union al asgpr para la degradacion de proteinas extracelulares.
EP4651904A1 (en) 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. Lysosomal targeting bifunctional molecules for degradation of autoantibodies
AU2024208960A1 (en) 2023-01-18 2025-07-24 Lycia Therapeutics, Inc. Asgpr binding compounds and conjugates
EP4651901A1 (en) 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. Cycling lysosomal targeting antibody conjugates
WO2024167900A2 (en) * 2023-02-06 2024-08-15 Biohaven Therapeutics Ltd. Bifunctional molecules to target degradation of tumor necrosis factor
CN121866074A (zh) 2023-08-09 2026-04-14 利西亚治疗公司 用于降解肌肉特异性激酶自身抗体的溶酶体靶向双官能分子
CN116854754B (zh) 2023-09-01 2023-12-12 北京悦康科创医药科技股份有限公司 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物
TW202516008A (zh) * 2023-09-27 2025-04-16 大陸商上海拓界生物醫藥科技有限公司 含三唑基化合物、製備方法及用途
WO2025199666A1 (en) * 2024-03-25 2025-10-02 Canwell Biotech Limited Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof
TW202602932A (zh) 2024-03-28 2026-01-16 美商萊西亞醫療公司 用於降解甲狀腺刺激荷爾蒙受體自體抗體之胞溶體靶向雙功能分子
WO2025252118A1 (zh) * 2024-06-06 2025-12-11 苏州瑞博生物技术股份有限公司 整联蛋白αvβ6特异性配体化合物、缀合物、药物组合物及其用途
WO2026015664A1 (en) 2024-07-10 2026-01-15 Lycia Therapeutics, Inc. Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige)
US12685782B2 (en) 2024-07-31 2026-07-21 Biohaven Therapeutics Ltd. Bifunctional degraders for the treatment of Graves' disease
WO2026120177A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Novel long-acting degrader conjugates
CN120285222B (zh) * 2025-04-15 2025-11-18 上海交通大学 一种靶向肝脏的药物靶向递送系统及其治疗和/或辅助治疗代谢相关脂肪性肝病的药物

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
AU2752892A (en) 1991-09-26 1993-04-27 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids
GB9323429D0 (en) 1993-11-12 1994-01-05 Wellcome Found Therapy
DK129293D0 (da) 1993-11-16 1993-11-16 Carlsberg Lab Carbonhydratholdige forbindelser, der kan binde sig til carbonhydratbindende receptorer
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US20020168761A1 (en) 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
CA2318981A1 (en) 1998-02-09 1999-08-12 Genzyme Corporation Nucleic acid delivery vehicles
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
AU770340B2 (en) 1998-10-08 2004-02-19 Biorion Technologies B.V. Peptide-based carrier devices for stellate cells
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
WO2001050127A2 (en) 1999-12-30 2001-07-12 7Tm Pharma Screening using biological target molecules with metal-ion binding sites
US20040009907A1 (en) 2001-02-26 2004-01-15 Alsobrook John P. Proteins and nucleic acids encoding same
WO2001080883A1 (en) 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
DE10138935B4 (de) * 2000-08-11 2007-08-02 Kotobuki Pharmaceutical Co., Ltd, , Hanishina Synthetische Verbindungen vom Nicht-Mucintyp oder ihre mit einem Träger konjugierten Verbindungen, unter deren Verwendung hergestellte monoclonale Antikörper, diese umfassende Antitumormittel Immunstimulantien und Mittel gegen das humane Immundefizienzvirus
NZ524980A (en) 2000-09-01 2005-10-28 Biogen Idec Inc Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
ES2404689T3 (es) 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US20050191309A1 (en) 2002-05-06 2005-09-01 Kakkis Emil D. Induction of antigen specific immunologic tolerance
ES2438008T3 (es) 2002-05-06 2014-01-15 Endocyte, Inc. Agentes de formación de imágenes dirigidos a vitaminas
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
PT1628987E (pt) 2003-05-20 2009-10-29 Pharmaxis Pty Ltd Compostos manose-6-fosfonato para o tratamento de doenças inflamatórias
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
GB0423405D0 (en) 2004-10-21 2004-11-24 Novartis Ag Organic compounds
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
EP1745802A1 (en) 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
WO2008020827A2 (en) 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
US20070104648A1 (en) 2005-11-09 2007-05-10 Glyconix Corporation Compositions, methods of preparing amino acids, and nuclear magnetic resonance spectroscopy
EP2009990B1 (en) 2006-04-07 2016-09-21 The Board of Regents of The University of Texas System Methods and compositions related to adenoassociated virus-phage particles
US20080057072A1 (en) 2006-08-31 2008-03-06 Alcon Manufacturing, Ltd. Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
JP5244810B2 (ja) 2006-11-10 2013-07-24 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
WO2008089339A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
JP5675619B2 (ja) 2008-09-17 2015-02-25 エンドサイト, インク.Endocyte, Inc. 葉酸拮抗薬の葉酸受容体結合性コンジュゲート
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
EP3608330B1 (en) 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
WO2010108048A2 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
JP2012525369A (ja) 2009-04-28 2012-10-22 ファーマキシス リミテッド 創傷および線維性障害の治療のためのホスホテトラヒドロピラン化合物
EP2448600B1 (en) 2009-07-03 2016-03-30 INSERM - Institut National de la Santé et de la Recherche Médicale Compounds targeting the cation-independent mannose 6-phosphate receptor
WO2011038234A2 (en) 2009-09-24 2011-03-31 University Of Louisville Research Foundation, Inc. Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions
FR2952372B1 (fr) 2009-11-10 2012-03-23 Centre Nat Rech Scient Nouveaux derives de mannopyranoside ayant une activite anticancereuse
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
FR2960153B1 (fr) 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant
SG186451A1 (en) 2010-07-12 2013-01-30 Covx Technologies Ireland Ltd Multifunctional antibody conjugates
US20120121592A1 (en) 2010-10-13 2012-05-17 Baylor Research Institute Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
LT2714752T (lt) 2011-05-27 2018-03-12 Amicus Therapeutics, Inc. Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui
SG10201704846VA (en) 2012-03-14 2017-07-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
WO2014082080A2 (en) 2012-11-26 2014-05-30 Callidus Biopharma, Inc. Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
WO2014089209A2 (en) 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
JP2016514096A (ja) 2013-02-20 2016-05-19 バレリオン セラピューティクス, エルエルシー ポンぺ病の処置のための方法および組成物
WO2014178878A1 (en) 2013-05-03 2014-11-06 Yale University Synthetic antibody mimetic compounds (syams) targeting cancer, especially prostate cancer
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
US9943604B2 (en) * 2013-09-20 2018-04-17 Ionis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
WO2015069587A2 (en) 2013-11-06 2015-05-14 Merck Sharp & Dohme Corp. Peptide containing conjugates for dual molecular delivery of oligonucleotides
CA2946064C (en) * 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
RU2696490C2 (ru) 2014-05-19 2019-08-02 Пфайзер Инк. Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR
WO2015191934A2 (en) 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
WO2016025519A1 (en) 2014-08-11 2016-02-18 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
US20170290806A1 (en) 2014-09-08 2017-10-12 Temple University-Of The Commonwealth System Of Higher Education PCSK9 Inhibitors and Methods of Use Thereof
PL3204425T3 (pl) 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
US20160166679A1 (en) 2014-12-12 2016-06-16 Purdue Research Foundation Method of treatment using folate conjugates and tyrosine kinase inhibitors
JP6993958B2 (ja) 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
FR3041345B1 (fr) 2015-09-18 2019-06-14 Nanomedsyn Composes polysaccharides multi-fonctionnalises et leur utilisation pour cibler le recepteur du mannose 6-phosphate cation-independant
EP4477269A3 (en) 2015-09-20 2025-03-19 The United States of America, as Represented By the Secretary, Department of Health and Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
WO2017096164A1 (en) 2015-12-02 2017-06-08 The Board Of Trustees Of The Leland Stanford Junior University Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
MY207684A (en) 2015-12-08 2025-03-12 Regeneron Pharma Compositions and methods for internalizing enzymes
HRP20231451T1 (hr) 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
KR20180104148A (ko) 2016-02-05 2018-09-19 젠맵 에이/에스 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
JP7100629B2 (ja) 2016-06-09 2022-07-13 セントレ・ナショナル・デ・ラ・レシェルシェ・サイエンティフィーク 化学修飾されたカプシドを有するraav
KR102085798B1 (ko) 2016-12-28 2020-03-06 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CA3134765A1 (en) 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
CA3134610A1 (en) 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
EP3873486A4 (en) * 2018-11-02 2022-10-19 Arbutus Biopharma Corporation Bivalent targeted conjugates
EP3897747A4 (en) 2018-12-19 2022-12-07 The Board of Trustees of the Leland Stanford Junior University BIFUNCTIONAL MOLECULES FOR LYSOSOMA TARGETING AND RELATED COMPOSITIONS AND METHODS
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
GB201908108D0 (en) 2019-06-06 2019-07-24 King S College London Product
CA3143995A1 (en) 2019-06-21 2020-12-24 Single Cell Technology, Inc. Anti-tigit antibodies
EP3997214B1 (en) 2019-07-11 2023-08-02 Centre National de la Recherche Scientifique Chemically-modified adeno-associated virus
US20250269043A1 (en) 2019-10-10 2025-08-28 Yale University Targeted bifunctional degraders
US20240342293A1 (en) 2019-10-10 2024-10-17 Yale University Engineered antibodies as molecular degraders through cellular receptors
WO2021119325A1 (en) * 2019-12-12 2021-06-17 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
EP4087584A4 (en) 2020-01-10 2024-08-28 Lycia Therapeutics, Inc. Cell surface receptor binding compounds and conjugates
MX2022009419A (es) 2020-01-31 2022-08-25 Avilar Therapeutics Inc Compuestos de union al asgpr para la degradacion de proteinas extracelulares.
EP4100064A1 (en) 2020-02-07 2022-12-14 Novartis AG Targeted plasma protein degradation
EP4168410A1 (en) 2020-06-22 2023-04-26 The United States of America, as represented by the Secretary, Department of Health and Human Services Methotrexate analogs and methods of use
US20230226214A1 (en) 2020-06-24 2023-07-20 Lycia Therapeutics, Inc. Bifunctional bridging compositions for viral transduction
EP4171658A4 (en) 2020-06-24 2025-04-09 Lycia Therapeutics, Inc. Modified viral compositions for viral transduction
CN113943288A (zh) 2020-07-17 2022-01-18 微境生物医药科技(上海)有限公司 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
WO2022035997A1 (en) 2020-08-11 2022-02-17 Avilar Therapeutics, Inc. In vivo assembly of asgpr binding therapeutics
EP4274619A4 (en) 2021-01-08 2025-09-24 Lycia Therapeutics Inc BIFUNCTIONAL FOLATE RECEPTOR-BINDING COMPOUNDS
EP4281115A1 (en) 2021-01-19 2023-11-29 Novartis AG Degradation of extracellular targets
BR112023016690A2 (pt) 2021-02-22 2023-11-14 Univ Yale Degradadores bifuncionais direcionados e métodos usando os mesmos
WO2022192478A1 (en) 2021-03-10 2022-09-15 Biohaven Therapeutics Ltd. Bifunctional degraders of galactose-deficient immunoglobulins
AU2022268925A1 (en) 2021-05-03 2023-11-16 Avilar Therapeutics, Inc. Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins
EP4359430A4 (en) 2021-06-23 2025-07-16 Lycia Therapeutics Inc BIFUNCTIONAL COMPOUNDS CONTAINING IGF-2 POLYPEPTIDES
US20250127913A1 (en) 2021-06-24 2025-04-24 Lycia Therapeutics, Inc. Bifunctional folate receptor binding compounds
CN117915956A (zh) 2021-07-14 2024-04-19 利西亚治疗公司 M6pr细胞表面受体结合化合物和缀合物
WO2023009554A1 (en) 2021-07-26 2023-02-02 Avilar Therapeutics, Inc. Methods to reduce adverse effects of gene or biologics therapy
KR20240099143A (ko) 2021-08-27 2024-06-28 예일 유니버시티 세포외 단백질의 분자 분해제
WO2023028338A2 (en) 2021-08-27 2023-03-02 Avilar Therapeutics, Inc. Mannose 6-phosphate or asgpr receptor binding compounds for the degradation of extracellular proteins
WO2023028590A1 (en) 2021-08-27 2023-03-02 Yale University Molecular degraders of extracellular proteins
JP2025509730A (ja) 2022-03-15 2025-04-11 イエール ユニバーシティ 循環タンパク質の選択的分解を目的とした二官能性小分子
EP4611818A2 (en) 2022-11-03 2025-09-10 Avilar Therapeutics, Inc. Asgpr-binding heterobifunctional compounds for the degradation of immunoglobulins

Also Published As

Publication number Publication date
US20230250091A1 (en) 2023-08-10
CN117957020A (zh) 2024-04-30
AU2022310356A1 (en) 2024-01-25
CA3226269A1 (en) 2023-01-19
US20250101007A1 (en) 2025-03-27
JP2024524614A (ja) 2024-07-05
EP4370157A1 (en) 2024-05-22
WO2023288033A1 (en) 2023-01-19
US12258332B2 (en) 2025-03-25
WO2023288033A8 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
US12258332B2 (en) ASGPR cell surface receptor binding compounds and conjugates
US20240335544A1 (en) M6pr cell surface receptor binding compounds and conjugates
AU2021206280A1 (en) Cell surface receptor binding compounds and conjugates
JP2026503462A (ja) 自己抗体の分解のためのリソソーム標的化二官能性分子
WO2022150721A1 (en) Bifunctional folate receptor binding compounds
JP2026503463A (ja) Asgpr結合化合物およびコンジュゲート
TW202406574A (zh) 一種包含親水性糖結構的配體-藥物偶聯物
JP2026503461A (ja) サイクリングリソソーム標的化抗体コンジュゲート
WO2022272307A1 (en) Bifunctional folate receptor binding compounds
KR20230133289A (ko) 화합물 또는 이의 염, 및 이들에 의해 얻어지는 항체
WO2025207934A1 (en) Lysosomal targeting bifunctional molecules for degradation of thyroid stimulating hormone receptor autoantibodies
JP2025526869A (ja) アントラサイクリン及びそのコンジュゲート
EP4651903A1 (en) M6pr binding compounds and conjugates
WO2025035040A1 (en) Lysosomal targeting bifunctional molecules for degradation of muscle-specific kinase autoantibodies
KR20260025153A (ko) 넥틴-4 항체 및 항체-약물 접합체

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201